#SP500 #CAC40 We’ve received a few emails regarding 4d Pharma, share code DDDD and it appears those getting in touch have ample reason for their interest. A glance at their news release history obviously unearthed the inevitable mention of Covid-19 tests, along with a rather intimidating number of fields the company appear to be active. It’s an interesting one and thankfully, their share price looks poised to repay the interest.
Historically, 4d Pharma has experienced a pretty rough ride, the price nearly reaching the 11 quid mark before experiencing relentless reversals since 2016. There are a couple of items worthy of comment, hopefully able to prove important for the longer term.
Firstly, the Covid-19 drop in March took the share to an arithmetically perfect bottom of 24p. We cannot calculate below this level but who cares? The bounce in the period since has been pretty impressive.
Secondly, the market opted to Gap (manipulate) the share price above the Blue downtrend in April, hopefully sending a clear signal that everything has changed and an entirely new trend is commencing. If we take this Gap at face value, it was supposed to generate price recovery to 139p, something the share achieved earlier this month and now, the price has actually closed above 139p. This should prove significant as movement next above 149p looks capable of driving recovery to 181p initially. If exceeded, our secondary calculates at 235p.
Visually, there’s an expectation the 235p level shall provoke some sort of hesitation but closure above this level should prove really game changing for the longer term, the share entering a region where 651p works out as possible.
For the present, we’re fairly optimistic against this one, the price needing trade below 84p before justifying raising an eyebrow.
|Time Issued||Market||Price At Issue||Short Entry||Fast Exit||Slow Exit||Stop||Long Entry||Fast Exit||Slow Exit||Stop||Prior|